Shop by goal
Popular compounds
Research resources
Recently viewed
Semaglutide: Metabolic / Fat Loss research guide
In short: Semaglutide, long-acting GLP-1 receptor agonist with 94% human GLP-1 homology, C18 fatty diacid albumin binding, and 7-day pharmacokinetic half-life. It is studied in preclinical (cell and animal) research and is supplied strictly for laboratory use — not for human or clinical use.
Not medical advice. Semaglutide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Semaglutide at a glance
What Semaglutide is
Semaglutide is a GLP-1 receptor agonist studied heavily for incretin biology, glucose regulation, and appetite circuits in research animals and clinical trial literature (outside our sales jurisdiction).
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Semaglutide, long-acting GLP-1 receptor agonist with 94% human GLP-1 homology, C18 fatty diacid albumin binding, and 7-day pharmacokinetic half-life.
Quick takeaways
Research contexts
Peer-reviewed literature typically discusses Semaglutide in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Typical study contexts
Why Metabolic / Fat Loss research matters
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Mechanisms (technical review)
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Lab handling & preparation
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 0.25–2.4 mg subcutaneously (dose escalation) · Once weekly subcutaneous injection · t½ ≈ 7 days (165–184 h); steady-state in 4–5 weeks; Vd ~12.5 L (SC); >99% albumin bound; SC bioavailability ~89%; oral bioavailability 0.4–1%; clearance ~0.035 L/h; ~3% excreted unchanged in urine. Metabolized via proteolytic cleavage and fatty acid β-oxidation; no CYP-mediated interactions.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Common Questions People Are Asking
What is semaglutide?
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist — the peptide best known as the active ingredient in Novo Nordisk's Ozempic and Wegovy. Semaglutide is the research-grade form of this semaglutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is NOT Ozempic or Wegovy, is not an approved medicine, and is not for human use.
How does semaglutide work?
In the research literature semaglutide binds and activates the GLP-1 receptor, which slows gastric emptying, acts on hypothalamic appetite centres, and enhances glucose-dependent insulin secretion. The fatty-acid/albumin modification extends its half-life to about a week. These are mechanisms described in published studies of the molecule, not human-use guidance — Semaglutide is supplied for research only.
Is Semaglutide the same as Ozempic or Wegovy?
It is the same active peptide (semaglutide), but it is NOT the same product. Ozempic and Wegovy are FDA-approved, prescription, sterile finished pharmaceuticals manufactured under cGMP. Semaglutide is an unapproved, research-grade lyophilised powder sold for laboratory research use only — not for human consumption, and not a substitute for any prescribed medication.
Is semaglutide safe?
As an approved prescription medicine, semaglutide has been extensively studied in human trials under medical supervision. That clinical record does NOT extend to research-grade material: Semaglutide is unapproved, is not manufactured as a sterile human drug, and has no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.
How is Semaglutide different from native GLP-1?
Semaglutide shares 94% of its sequence with human GLP-1 but has three engineered modifications: an Aib substitution at position 8 that blocks degradation by DPP-IV, an Arg at position 34, and a C18 fatty diacid attached to Lys26. The fatty acid binds to albumin, extending half-life from ~2 minutes to ~7 days.
Why does Semaglutide produce larger body-composition effects than first-generation GLP-1 agonists?
Semaglutide reaches meaningful GLP-1 receptor occupancy in the hypothalamus, where it directly suppresses appetite, while also slowing gastric emptying. The combined central and peripheral effects produce a much larger and more durable energy-balance shift than earlier GLP-1 agonists could achieve.
Semaglutide vs tirzepatide — what is the difference?
Semaglutide activates a single receptor (GLP-1), while tirzepatide is a dual agonist that adds the GIP receptor on top of GLP-1. In the head-to-head SURMOUNT-5 trial (NEJM 2025) tirzepatide produced larger mean body-weight reduction than semaglutide (20.2% vs 13.7% at 72 weeks), although semaglutide carries the broader cardiovascular- and kidney-outcomes dataset to date. Both are described here only as descriptive research context, and each is supplied as unapproved, research-grade material for laboratory use, not for human use.
Can semaglutide be combined with cagrilintide?
In the research literature the two are studied together as CagriSema, because semaglutide (a GLP-1 agonist) and cagrilintide (an amylin/calcitonin-receptor agonist) act on distinct, additive appetite circuits. The Phase 3 REDEFINE 1 trial (NEJM 2025) of that co-formulation reported a larger mean body-weight reduction than either component alone. This is descriptive clinical-trial context for the molecules, not a protocol for any use of this research-grade material.
Is Semaglutide an approved medicine?
No. Semaglutide is supplied as a research-grade lyophilised powder for in-vitro and preclinical research only. It is not a licensed pharmaceutical product and is not a substitute for any prescribed medication.
How should Semaglutide be stored?
Store the lyophilised powder in a freezer at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Avoid repeated warming and cooling cycles, as the fatty acid tail is sensitive to prolonged heat exposure.
What happens when you stop taking GLP-1s?
In the published clinical literature on the reference drug (for example the STEP-1 extension study of semaglutide), discontinuing a GLP-1 receptor agonist is followed by the return of appetite signalling and gradual regain of much of the lost body weight over roughly a year, because the receptor stimulation that slowed gastric emptying and curbed appetite is withdrawn. Those observations come from trials of the approved medicines in human subjects — Semaglutide is an unapproved research-grade peptide supplied for laboratory research only and is not for human use.
Is this page medical advice? Can I use Semaglutide for my health?
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Where do I find Semaglutide specs, purity certificates and pricing?
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Related peptide guides
Other compounds researchers often read about alongside Semaglutide.
Scientific sources & further reading
Primary literature and registries for Semaglutide, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Ready to order? View full product specs
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Semaglutide Acetate, GLP-1 Receptor Agonist
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io